Yoichi Nishigaki

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara et al. · The Lancet Infectious Diseases · 2015 · 361 citations

Hepatology, Hepatitis C, Viral Hepatitis +8

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV</scp> infection: an open‐label, phase 3 trial

Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno et al. · Journal of Viral Hepatitis · 2014 · 201 citations · Full text

Japanese Patients, Hcv Infection, Hepatology +13

Therapeutic Effect of Balloon-occluded Retrograde Transvenous Obliteration on Portal-systemic Encephalopathy in Patients with Liver Cirrhosis.

Tomohiro Kato, Takahiro Uematsu, Yoichi Nishigaki et al. · Internal Medicine · 2001 · 74 citations · Full text

Hepatocellular carcinoma patients with increased oxidative stress levels are prone to recurrence after curative treatment: a prospective case series study using the d-ROM test

Yusuke Suzuki, Kenji Imai, Koji Takai et al. · Journal of Cancer Research and Clinical Oncology · 2013 · 49 citations · Full text

Hepatology, Hepatocellular Carcinoma Patients, Medicine +10

Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus‐positive patients: A prospective, case series study

Kenji Imai, Koji Takai, Yoichi Nishigaki et al. · Hepatology Research · 2010 · 43 citations